WO2016166703A1 - Ribociclib tablet - Google Patents

Ribociclib tablet Download PDF

Info

Publication number
WO2016166703A1
WO2016166703A1 PCT/IB2016/052136 IB2016052136W WO2016166703A1 WO 2016166703 A1 WO2016166703 A1 WO 2016166703A1 IB 2016052136 W IB2016052136 W IB 2016052136W WO 2016166703 A1 WO2016166703 A1 WO 2016166703A1
Authority
WO
WIPO (PCT)
Prior art keywords
ribociclib
tablet
coating
core
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/052136
Other languages
English (en)
French (fr)
Inventor
Bindhumadhavan GURURAJAN
Arnaud Grandeury
Rui Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016166703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES16718020T priority Critical patent/ES2938261T3/es
Priority to SI201631661T priority patent/SI3283058T1/sl
Priority to EA201792290A priority patent/EA201792290A1/ru
Priority to CN202211237232.XA priority patent/CN115554257A/zh
Priority to CA2982425A priority patent/CA2982425C/en
Priority to US15/564,534 priority patent/US10799506B2/en
Priority to MX2017013350A priority patent/MX2017013350A/es
Priority to AU2016248017A priority patent/AU2016248017A1/en
Priority to KR1020257000051A priority patent/KR20250009572A/ko
Priority to PL16718020.7T priority patent/PL3283058T3/pl
Priority to EP16718020.7A priority patent/EP3283058B1/en
Priority to SG11201708084PA priority patent/SG11201708084PA/en
Priority to TNP/2017/000422A priority patent/TN2017000422A1/en
Priority to EP25194967.3A priority patent/EP4620458A3/en
Priority to EP22203730.1A priority patent/EP4197530B1/en
Priority to KR1020177029433A priority patent/KR102750931B1/ko
Priority to HRP20230053TT priority patent/HRP20230053T1/hr
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201680022122.8A priority patent/CN107530292B/zh
Priority to BR112017021283A priority patent/BR112017021283A2/pt
Priority to FIEP16718020.7T priority patent/FI3283058T3/fi
Priority to JP2017553915A priority patent/JP2018514523A/ja
Priority to DK16718020.7T priority patent/DK3283058T3/da
Publication of WO2016166703A1 publication Critical patent/WO2016166703A1/en
Priority to IL254818A priority patent/IL254818A0/en
Priority to PH12017501820A priority patent/PH12017501820A1/en
Priority to CONC2017/0010510A priority patent/CO2017010510A2/es
Anticipated expiration legal-status Critical
Priority to AU2019201929A priority patent/AU2019201929B2/en
Priority to US17/003,771 priority patent/US20200390771A1/en
Priority to AU2020250190A priority patent/AU2020250190A1/en
Priority to US17/805,956 priority patent/US12064434B2/en
Priority to AU2022215155A priority patent/AU2022215155B2/en
Priority to US18/588,259 priority patent/US20250090531A1/en
Priority to AU2024227794A priority patent/AU2024227794A1/en
Priority to US18/977,210 priority patent/US20250134893A1/en
Priority to US18/977,228 priority patent/US12419894B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present disclosure relates to tablet formulation of ribociclib and/or its pharmaceutically acceptable salts, as well as methods of treatment using the same.
  • ribociclib is known as ribociclib. Its chemical name is 7-cyclopentyl -N,N -dimethyl -2- ⁇ [5- (piperazin-l-yl)pyridin-2-yl]amino ⁇ -7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and its synthesis is specifically described in WO 2010/020675 Al, Example 74.
  • cyclin dependent kinases in particular, cyclin dependent kinases selected from CDK1, CDK2, CDK3,.CDK4, CDK5, CDK6 and CDK9; and (2) as modulators and/or inhibitors of glycogen synthase kinase-3 (GSK-3).
  • Ribociclib is also known under the code name LEEO 11.
  • the present disclosure is directed to oral formulations of ribociclib including its salt(s) and/or solvate(s).
  • One embodiment of the present disclosure is directed to tablet formulations of ribociclib with high drug load with an immediate release profile.
  • One embodiment of the present disclosure is directed to coated tablet formulations of ribociclib.
  • Another embodiment of the present disclosure is directed to coated tablet formulations of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
  • FIGS. 1A and IB depict a process flow diagram for making ribociclib tablets. Uncoated tablets are made according to Steps 1-8. Coated tablets are made according to Steps 1-9.
  • FIG. 2 shows the images of the tablets manufactured with Opadry® (standard HPMC based) and with Opadry® amb II (advance moisture barrier (AMB) coating material with PVA based).
  • Opadry® standard HPMC based
  • Opadry® amb II advanced moisture barrier (AMB) coating material with PVA based
  • FIG. 3. shows the Dynamic Vapor Sorption (DVS) data of the ribociclib tablets coated with standard Opadry® and Opadry® amb II.
  • FIG. 4 shows the dissolution profile of ribociclib (LEE011) tablets coated with Opadry® amb II obtained with the rotating basket at 100 rpm with dissolution media having different pH values, at 37 °C.
  • the present disclosure relates to a solid oral tablet dosage form of ribociclib or its pharmaceutically acceptable salt.
  • Such formulation has very good process performance and high stability.
  • the tablet of the present disclosure has an immediate release profile. These tablets release at least 75%(Q) (where Q refers to the acceptance criteria defined by USP chapter ⁇ 711>) of the active after 45 minutes under standard dissolution test. In embodiment, the tablets release at least 75% of the active after 45 minutes when using the rotating basket at 100 rpm, with 900 ml of HC1 pH 1 as dissolution medium at 37 °C. In another embodiment, the tablets release at least 75% of the active after 45 minutes when using the rotating basket at 100 rpm, with 900 ml of HC1 pH 2 as dissolution medium at 37 °C.
  • the tablets release at least 75% of the active after 45 minutes when using the rotating basket at 100 rpm, with 900 ml of acetate buffer pH 4.5 as dissolution medium at 37 °C. In another embodiment, the tablets release at least 75% of the active after 45 minutes when using the rotating basket at 100 rpm, with 900 ml of phosphate buffer pH 6.8 as dissolution medium at 37 °C.
  • the tablets of the present disclosure can be coated or uncoated.
  • the tablets of the present disclosure have high drug load of at least 40%, 45%, 50%, 55% or 60%, when measured in w/w percentage of the ribociclib succinate of the core tablet.
  • the tablets of the present disclosure have high drug load of at least 32%, 40%, 44%, 47% or 52%, when measured in w/w percentage of the ribociclib free base of the core tablet.
  • the % of ribociclib succinate (w/w) is at least 40% of the core tablet. In one embodiment, the % of ribociclib succinate (w/w) is at least 50% of the core tablet. In another embodiment, the % of ribociclib succinate (w/w) is at least 55% of the core tablet. In another embodiment, the % of ribociclib succinate (w/w) is at about 55% to 65% of the core tablet. In another embodiment, the % of ribociclib succinate (w/w) is at about 60% of the core tablet.
  • the % of ribociclib (w/w) is at least 32% of the core tablet. In one embodiment, the % of ribociclib (w/w) is at least 40% of the core tablet. In another embodiment, the % of ribociclib (w/w) is at least 44% of the core tablet. In another embodiment, the % of ribociclib (w/w) is at about 44% to 52% of the core tablet. In another embodiment, the % of ribociclib (w/w) is at about 47% of the core tablet.
  • Core tablet is also referred to as "tablet core”.
  • the tablet core is the whole tablet.
  • the tablet core is the portion of the tablet excluding the coating.
  • the tablet formulation according to the disclosure may contain pharmaceutically acceptable excipients commonly used in pharmaceutical formulations, particularly those for oral administration for example, as fillers, binders, disintegrants and lubricants.
  • Fillers for example, can be cellulose, mannitol, di-calcium phosphate, lactose, microcrytalline cellulose, alone or in combination thereof.
  • Binders for example, can be hydroxypropyl cellulose, polyvinyl-pyrrolidone, alone or in combination thereof.
  • Disintegrants for example, can be crosslinked polyvinyl-pyrrolidone, crosslinked sodium carboxymethyl cellulose, low substituted hydroxypropyl cellulose, sodium starch glycolate, alone or in combination thereof.
  • Lubricants for example, can be magnesium stearate, stearic acid, talc, silicon dioxide, sodium stearyl fumarate, alone or in combination thereof.
  • FIGS. 1A and IB show the process flow diagram of making ribociclib tablets. Uncoated tablets are made according to Steps 1-8. Coated tablets are made according to Steps 1-9.
  • the core ribociclib tablets have an inner phase comprising ribociclib or salt(s) thereof, and an outer phase.
  • the ribociclib tablets of the present disclosure are immediate release tablets and can be coated with any immediate release coating materials.
  • the coating material can be Opadry®, Opadry® 200, Opadry® amb II, Opadry® fxTM, Opadry® II, Opalux®, or mixtures thereof.
  • Opadry®, Opadry® 200, Opadry® amb II, Opadry® fxTM, Opadry® II, and Opalux® are all commercially available through Colorcon, Inc.
  • the coating material is Opadry®.
  • Opadry® is a HPMC (hydroxypropyl methylcellulose) coating material and has the following composition: HPMC (Pharmacoat 603) 71.4%, polyethylene glycol 7.15%, talc 7.15%, and iron oxide 14.3%.
  • the coating material is Opadry® amb II.
  • Opadry® amb II is a PVA (polyvinyl alcohol) based coating material and has the following composition: polyvinyl alcohol 45.52%, iron oxide 32%, talc 20%, lecithin (soya) 2%, and xanthan gum 0.48%.
  • the ribociclib tablets When the ribociclib tablets are coated with Opadry® amb II, the tablets show improved appearances and are essentially free of cracking defects.
  • Table 1 below details the composition of uncoated 50 mg and 200mg ribociclib tablets. These tablets are made according to Steps 1-8 of the process flow diagram (FIGS. 1A-1B). Table 1. Composition per dosage form unit
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • Table 2 below details the composition of uncoated 100 mg, 150 mg, and 300mg ribociclib tablets. These tablets are made according to Steps 1-8 of the process flow diagram (FIGS. 1A-1B).
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • Table 3 below details the composition of film-coated 50 mg and 200mg ribociclib tablets. These tablets were made according to Steps 1-9 of the process flow diagram (FIGS. 1A-1B).
  • the coating material is Opadry® amb II, which is commercially available and is an advanced moisture barrier (AMB) coating, PVA based.
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • the coating premix is a commercially available product
  • Table 4 below details the composition of film-coated 100 mg, 150 mg and 300mg ribociclib tablets. These tablets are made according to Steps 1-9 of the process flow diagram (FIGS. 1A-1B).
  • the coating material is Opadry® amb II, which is commercially available and is an advanced moisture barrier (AMB) coating, PVA based.
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • the coating premix is a commercially available product
  • Ribociclib tablets coated with different coatings were compared. Coating was carried out in Bohle coater 1 Kg scale with spray rate of 3g/ min. With standard Opadry® coating, tablet logo bridging issue and tablet cracking defects were observed. In contrast, no cracking was observed with the PVA based Opadry® amb II coated tablets.
  • Fig. 2 shows the images of the tablets manufactured with Opadry® (standard HPMC based) and with Opadry® amb II (advance moisture barrier (AMB) coating material with PVA based).
  • Opadry® standard HPMC based
  • Opadry® amb II advanced moisture barrier (AMB) coating material with PVA based
  • FIG. 4 shows the dissolution profile of the Opadry® amb II film-coated ribociclib tablet in different pH media.
  • EXAMPLE 8 Coated (with Opadry® amb II Coating) 50 mg and 200mg ribociclib tablets with different coating premix combination
  • Table 5 below details the composition of film-coated 50 mg and 200mg ribociclib tablets with different coating premix combination compared to Example 3. These tablets were made according to Steps 1-9 of the process flow diagram (FIGS. 1A-1B).
  • the coating material is Opadry® amb II, which is commercially available and is an advanced moisture barrier (AMB) coating, PVA based. Table 5.
  • Composition per dosage form unit is
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • the coating premix is a commercially available product
  • EXAMPLE 9 Coated (with Opadry® amb II Coating) 100 mg, 150mg and 300mg ribociclib tablets with different coating premix combination
  • Table 6 below details the composition of film-coated 100 mg, 150 mg and 300mg ribociclib tablets with different coating premix combination compared to Example 4. These tablets are made according to Steps 1-9 of the process flow diagram (FIGS. 1A-1B).
  • the coating material is Opadry® amb II, which is commercially available and is an advanced moisture barrier (AMB) coating, PVA based.
  • the salt factor is 1 .272.
  • the drug substance quantity is increased if the content is ⁇ 99.5% with a corresponding reduction in the microcrystalline cellulose content.
  • the coating premix is a commercially available product

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2016/052136 2015-04-16 2016-04-14 Ribociclib tablet Ceased WO2016166703A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
DK16718020.7T DK3283058T3 (da) 2015-04-16 2016-04-14 Ribociclib-tablet
CN201680022122.8A CN107530292B (zh) 2015-04-16 2016-04-14 瑞博西尼片剂
EA201792290A EA201792290A1 (ru) 2015-04-16 2016-04-14 Таблетка, содержащая рибоциклиб
CN202211237232.XA CN115554257A (zh) 2015-04-16 2016-04-14 瑞博西尼片剂
CA2982425A CA2982425C (en) 2015-04-16 2016-04-14 Ribociclib tablet
US15/564,534 US10799506B2 (en) 2015-04-16 2016-04-14 Ribociclib tablet
MX2017013350A MX2017013350A (es) 2015-04-16 2016-04-14 Comprimido de ribociclib.
AU2016248017A AU2016248017A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet
KR1020257000051A KR20250009572A (ko) 2015-04-16 2016-04-14 리보시클립 정제
FIEP16718020.7T FI3283058T3 (fi) 2015-04-16 2016-04-14 Ribosiklibitabletti
EP16718020.7A EP3283058B1 (en) 2015-04-16 2016-04-14 Ribociclib tablet
SG11201708084PA SG11201708084PA (en) 2015-04-16 2016-04-14 Ribociclib tablet
TNP/2017/000422A TN2017000422A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet
EP25194967.3A EP4620458A3 (en) 2015-04-16 2016-04-14 Ribociclib tablet
EP22203730.1A EP4197530B1 (en) 2015-04-16 2016-04-14 Ribociclib tablet
KR1020177029433A KR102750931B1 (ko) 2015-04-16 2016-04-14 리보시클립 정제
HRP20230053TT HRP20230053T1 (hr) 2015-04-16 2016-04-14 Tableta ribocikliba
ES16718020T ES2938261T3 (es) 2015-04-16 2016-04-14 Comprimido de ribociclib
BR112017021283A BR112017021283A2 (pt) 2015-04-16 2016-04-14 comprimido de ribociclib
SI201631661T SI3283058T1 (sl) 2015-04-16 2016-04-14 Tableta ribocikliba
PL16718020.7T PL3283058T3 (pl) 2015-04-16 2016-04-14 Tabletka rybocyklibu
JP2017553915A JP2018514523A (ja) 2015-04-16 2016-04-14 リボシクリブ錠剤
IL254818A IL254818A0 (en) 2015-04-16 2017-10-01 Ribociclib tablet
PH12017501820A PH12017501820A1 (en) 2015-04-16 2017-10-04 Ribociclib tablet
CONC2017/0010510A CO2017010510A2 (es) 2015-04-16 2017-10-13 Tableta de ribociclib
AU2019201929A AU2019201929B2 (en) 2015-04-16 2019-03-20 Ribociclib tablet
US17/003,771 US20200390771A1 (en) 2015-04-16 2020-08-26 Ribociclib Tablet
AU2020250190A AU2020250190A1 (en) 2015-04-16 2020-10-06 Ribociclib tablet
US17/805,956 US12064434B2 (en) 2015-04-16 2022-06-08 Ribociclib tablet
AU2022215155A AU2022215155B2 (en) 2015-04-16 2022-08-08 Ribociclib tablet
US18/588,259 US20250090531A1 (en) 2015-04-16 2024-02-27 Ribociclib Tablet
AU2024227794A AU2024227794A1 (en) 2015-04-16 2024-10-31 Ribociclib Tablet
US18/977,228 US12419894B2 (en) 2015-04-16 2024-12-11 Ribociclib tablet
US18/977,210 US20250134893A1 (en) 2015-04-16 2024-12-11 Ribociclib Tablet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
US62/148,240 2015-04-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/564,534 A-371-Of-International US10799506B2 (en) 2015-04-16 2016-04-14 Ribociclib tablet
US17/003,771 Continuation US20200390771A1 (en) 2015-04-16 2020-08-26 Ribociclib Tablet

Publications (1)

Publication Number Publication Date
WO2016166703A1 true WO2016166703A1 (en) 2016-10-20

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/052136 Ceased WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Country Status (29)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4620458A3 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN115554257A (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (1) DK3283058T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (1) ES2938261T3 (enExample)
FI (1) FI3283058T3 (enExample)
HR (1) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (1) IL254818A0 (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (1) PL3283058T3 (enExample)
PT (1) PT3283058T (enExample)
SG (1) SG11201708084PA (enExample)
SI (1) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611772B2 (en) 2018-07-02 2020-04-07 Apotex Inc. Crystalline form of Ribociclib succinate
WO2021124106A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
WO2021124104A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP3283058B1 (en) 2015-04-16 2022-11-16 Novartis AG Ribociclib tablet
WO2023144684A1 (en) 2022-01-25 2023-08-03 Novartis Ag Ribociclib pharmaceutical compositions
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
WO2024201299A1 (en) 2023-03-27 2024-10-03 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230079187A (ko) * 2020-09-29 2023-06-05 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용
TWI866427B (zh) 2022-08-31 2024-12-11 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020675A1 (en) 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2012064805A1 (en) 2010-11-10 2012-05-18 Novartis Ag Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
IN2015DN01046A (enExample) * 2012-07-13 2015-06-26 Gtx Inc
PT2976106T (pt) * 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020675A1 (en) 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2012064805A1 (en) 2010-11-10 2012-05-18 Novartis Ag Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. GIRON: "Characterisation of Salts of Drug Substances", JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, vol. 73, 2003, pages 441 - 457, XP019254693
DANIEL TO ET AL: "A Novel Method to Evaluate On-Tablet Moisture Barrier Performance of Opadry® Film Coating Systems", AAPS POSTER REPRINT, 2014, pages 1 - 4, XP055785542, Retrieved from the Internet <URL:https://www.colorcon.com/es/products-formulation/all-products/download/512/2233/34?method=view>
J. GIMBEL ET AL: "Evaluation of a Novel, PEG-free Immediate Release Opadry® Aqueous Moisture Barrier Film Coating with High Productivity", AAPS POSTER REPRINT, 2014, pages 1 - 4, XP055785541, Retrieved from the Internet <URL:https://www.colorcon.com/jp/products-formulation/all-products/download/511/2245/34?method=view>

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064434B2 (en) 2015-04-16 2024-08-20 Novartis Ag Ribociclib tablet
US12419894B2 (en) 2015-04-16 2025-09-23 Novartis Ag Ribociclib tablet
EP3283058B1 (en) 2015-04-16 2022-11-16 Novartis AG Ribociclib tablet
US10611772B2 (en) 2018-07-02 2020-04-07 Apotex Inc. Crystalline form of Ribociclib succinate
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021124106A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
WO2021124104A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2023144684A1 (en) 2022-01-25 2023-08-03 Novartis Ag Ribociclib pharmaceutical compositions
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
WO2024201299A1 (en) 2023-03-27 2024-10-03 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Also Published As

Publication number Publication date
AU2020250190A1 (en) 2020-11-05
US20250134893A1 (en) 2025-05-01
ECSP17075052A (es) 2018-02-28
SI3283058T1 (sl) 2023-03-31
BR112017021283A2 (pt) 2018-06-26
CN107530292A (zh) 2018-01-02
EP4620458A2 (en) 2025-09-24
PE20180035A1 (es) 2018-01-09
KR20250009572A (ko) 2025-01-17
AU2024227794A1 (en) 2024-11-21
KR102750931B1 (ko) 2025-01-09
US20250127785A1 (en) 2025-04-24
US12064434B2 (en) 2024-08-20
AR104257A1 (es) 2017-07-05
SG11201708084PA (en) 2017-10-30
EP3283058A1 (en) 2018-02-21
CL2017002593A1 (es) 2018-05-18
EP4197530B1 (en) 2025-11-12
CO2017010510A2 (es) 2018-03-20
CA2982425C (en) 2023-10-31
EA201792290A1 (ru) 2018-02-28
AU2022215155B2 (en) 2024-08-01
PL3283058T3 (pl) 2023-03-20
CN107530292B (zh) 2022-11-01
AU2022215155A1 (en) 2022-09-01
ES2938261T3 (es) 2023-04-05
TN2017000422A1 (en) 2019-01-16
EP4197530A1 (en) 2023-06-21
PH12017501820A1 (en) 2018-04-23
TW201642864A (zh) 2016-12-16
US20250090531A1 (en) 2025-03-20
IL254818A0 (en) 2017-12-31
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
US10799506B2 (en) 2020-10-13
FI3283058T3 (fi) 2023-03-01
HUE061213T2 (hu) 2023-05-28
EP4620458A3 (en) 2025-10-22
DK3283058T3 (da) 2023-02-13
AU2019201929B2 (en) 2020-07-09
JP2018514523A (ja) 2018-06-07
KR20170137101A (ko) 2017-12-12
HRP20230053T1 (hr) 2023-03-03
CA2982425A1 (en) 2016-10-20
US20200390771A1 (en) 2020-12-17
AU2019201929A1 (en) 2019-04-11
US20230104792A1 (en) 2023-04-06
MX2017013350A (es) 2018-01-25
PT3283058T (pt) 2023-02-03
AU2016248017A1 (en) 2017-10-19
EP3283058B1 (en) 2022-11-16
CN115554257A (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
US12064434B2 (en) Ribociclib tablet
CA2847860A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
JP2024009815A (ja) アキシチニブを含有する医薬組成物
WO2015152680A1 (en) Granule comprising silodosin, and pharmaceutical composition and formulation comprising same
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
HK40089304A (en) Ribociclib tablet
JP6824549B2 (ja) 経口固形製剤およびその製造法
JP6210640B2 (ja) ホリナートカルシウム含有錠
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2018091609A1 (en) Formulation comprising 4-methylpyrazole
EA042324B1 (ru) Таблетка, содержащая рибоциклиб
HK1243319A1 (en) Ribociclib tablet
HK1243319B (en) Ribociclib tablet
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16718020

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 254818

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11201708084P

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 12017501820

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 15564534

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2982425

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 002096-2017

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 20177029433

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2017553915

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2017/0010510

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/013350

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017021283

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016248017

Country of ref document: AU

Date of ref document: 20160414

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2017000626

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: A201709786

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201792290

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112017021283

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171004